Novartis AG
FORMULATIONS COMPRISING 2-AMINO-2-[2-(4-OCTYLPHENYL)ETHYL]PROPANE-1,3-DIOL
Last updated:
Abstract:
A solid pharmaceutical composition suitable for oral administration, comprising: (a) a S1P receptor modulator; (b) a filler, and (c) a cyclodextrin.
Status:
Application
Type:
Utility
Filling date:
23 Apr 2019
Issue date:
15 Aug 2019